VA
RLMD icon

Verdad Advisers’s Relmada Therapeutics RLMD Stock Holding History

Verdad Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$602K Buy
86,994
+39,845
+85% +$278K 0.58% 63
2026
Q1 		$328K Buy
+47,149
New +$223K 0.37% 96

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Verdad Advisers's RLMD Position: Q2 2026 in Review

Verdad Advisers increased its Relmada Therapeutics (RLMD) stake by 85% in Q2 2026, buying an estimated $278K and bringing the position to 86,994 shares worth $602K. The position accounts for 0.58% of the portfolio, ranked #63.

Verdad Advisers first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Verdad Advisers held 86,994 shares of Relmada Therapeutics worth $602K as of Q2 2026.
  • Verdad Advisers bought 39,845 Relmada Therapeutics shares in Q2 2026, an estimated $278K.
  • Relmada Therapeutics made up 0.58% of Verdad Advisers's portfolio in Q2 2026, its #63 holding.
  • Verdad Advisers first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.